A NEW REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE SIMULTANEOUS ESTIMATION OF SERRATIOPEPTIDASE AND DICLOFENAC SODIUM IN BULK AND TABLET DOSAGE FORM by Kulkarni B, Manasi & Joshi M, Anagha
Vol 12, Issue 1, 2019
Online - 2455-3891 
Print - 0974-2441
A NEW REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR 
THE SIMULTANEOUS ESTIMATION OF SERRATIOPEPTIDASE AND DICLOFENAC SODIUM IN 
BULK AND TABLET DOSAGE FORM
MANASI KULKARNI B1,2*, ANAGHA JOSHI M3
1PhD Research Scholar, Punnaiyah Ramajayam Institute of Science and Technology, PRIST Deemed to be University, Thanjavur, Tamilnadu, 
India. 2Asst. Professor, Department of Pharmaceutical Chemistry, SCES’s Indira College of Pharmacy, Tathawade, Pune, Maharashtra, India. 
3Principal, SCES’s Indira College of Pharmacy, Tathawade, Pune, Maharashtra, India. Email: mansi.wagdarikar@indiraicp.edu.in
Received: 03 August 2018, Revised and Accepted: 10 September 2018
ABSTRACT
Objective: The objective is to study the development of a simple, rapid, specific, precise, and accurate reversed-phase high-performance liquid 
chromatography (RP-HPLC) method for the simultaneous estimation of serratiopeptidase (SER) and diclofenac (DC) sodium in bulk and tablet 
formulation.
Methods: RP-HPLC method was developed for the simultaneous estimation of SER and DC sodium in tablet formulation. The separation was achieved 
by Kromasil C18 column (250 mm × 4.6 mm, 5 µm particle size) with phosphate buffer pH-7 and o-phosphoric acid:methanol:acetonitrile (5:4:1% 
v/v/v). Flow rate was maintained at 1 mL/min and UV detection was carried at 270 nm.
Result: For RP-HPLC method, the retention time for SER and DC sodium was found to be 3.3833 min and 8.1667 min, respectively. The method was 
validated for accuracy, precision, and specificity. Linearity for SER and DC sodium was in the range of 5–50 µg/ml.
Conclusion: The developed RP-HPLC method is simple, accurate, rapid, sensitive, precise, and economic. Hence, this method can be employed 
successfully for the estimation of SER and DC sodium in both bulk and tablet dosage forms.
Keywords: Serratiopeptidase, Diclofenac sodium, Methanol, Acetonitrile, Phosphate buffer pH-7, O-phosphoric acid, Reversed-phase high-
performance liquid chromatography.
INTRODUCTION
Serratiopeptidase (SER) is a proteolytic enzyme (protease) produced 
by Enterobacter Serratia sp. E-15. This microorganism was originally 
isolated in the late 1960s from silkworm Bombyx mori L. (intestine). 
SER is present in the silkworm intestine and allows the emerging moth 
to dissolve its cocoon. SER is produced by purification from a culture 
of Serratia E 15 bacteria. SER is primarily indicated in the condition 
of hematoma, inflammation, edema osteoarthritis, and thrombosis. 
Diclofenac (DC) sodium is sodium 2-[(2, 6-dichlorophenyl)-amino] 
phenylacetate. It is a synthetic non-steroidal anti-inflammatory 
agent with analgesic, anti-inflammatory, and antipyretic activity. Its 
mechanism of action is associated principally with the inhibition of 
prostaglandin synthesis (specifically, inhibition of cyclooxygenase). 
DC sodium is administered to reduce inflammation and as an analgesic 
reducing pain in conditions such as arthritis or acute injury. It can also 
be used to reduce menstrual pain, dysmenorrhea (Figs. 1 and 2) [1-4].
Literature survey reveals few methods for the simultaneous estimation 
of SER and DC sodium in the combination considered in this work 
and other combinations. This initiates a need for more rigorously 
studied and competent reversed-phase high-performance liquid 
chromatography (RP-HPLC) method development and validation for 
SER and DC sodium in bulk and tablet dosage form.
METHODS
1. DC sodium (Zydus Cadila, PTC, Thane)
2. SER (Analab Fine Chemicals)
3. Marketed formulation: Emanzen-D (EMCURE Pharmaceuticals Pvt. 
Ltd.)
4. Acetonitrile (HPLC grade, Merck Ltd.)
5. Methanol (HPLC grade, Merck Ltd.)











•	 Mobile	phase:	phosphate	buffer	 (pH-7)	with	o-phosphoric	 acid	





Preparation of standard solutions
Preparation of diluent
Phosphate buffer pH 7 with OPA, methanol, and acetonitrile 
(5:4:1% v/v/v) mixtures was used as diluents and was filtered through 
0.22 µm nylon filter under vacuum condition. Then, it was sonicated for 
15 min and further used for the mobile phase preparation.
Preparation of SER and DC stock solution
Accurately weighed quantity of DC sodium equivalent to 10 mg and SER 
(10 mg) was transferred into two separate 10 mL volumetric flasks. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i1.28857
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The drug was dissolved in 10 mL of buffer pH-7.0 (HPLC grade) with 
shaking and sonicated for 10 min.
Preparation of tablet stock solution
An accurately weighed powder sample equivalent to 50 mg of DC 
and 10 mg of SER was transferred to 10 mL volumetric flask; 10 mL 
of phosphate buffer pH-7.0 was added and the flask was sonicated for 
5 min. The solution was filtered through 0.45 µ membrane filter paper. 
From the prepared solution, 0.1 mL of the filtrate was transferred to 
100 mL volumetric flask, and volume was made with mobile phase to 
get final concentration 50 µg/mL for DC and 10 µg/mL for SER.
Fig. 1: Crystal structure of serralysin with coordinated zinc (gray) 
and calcium (white)
Fig. 2: Structure of diclofenac sodium
Fig. 3: Reversed-phase high-performance liquid chromatography 
graph of bulk mixture (10 µg/mL SER and 50 µg/mL DC). Buffer 
(pH-7) with OPA:methanol:ACN (5:4:1 v/v/v), flow rate: 1.0 mL/min
Fig. 4: Standard calibration curve of diclofenac
Fig. 5: Standard calibration curve of serratiopeptidase
Fig. 6: Flow rate change - robustness: (1) Flow rate - 0.9 mL
Fig. 7: Flow rate change - robustness: (2) Flow rate - 1.0 mL
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Preparation of mix working standard solution of SER and DC
Working	 standard	 solution	was	prepared	by	diluting	0.1	mL	of	 stock	
solution SER and 0.5 mL of stock solution DC with diluents in 10 mL of 
volumetric flask up to the mark with mobile phase. To get 10 µg/mL for 
SER and 50 µg/mL for DC.
Preparation of tablet mixture
Tablet mixtures were prepared by pipetting out 0.1 mL from stock 
solution in 100 mL volumetric flask and diluted it with mobile phase 
upto the mark.
Preparation of mix sample solution of SER and DC
Working	 sample	 solutions	 were	 prepared	 by	 taking	 aliquots	 as	
mentioned in Table 1 from stock solution in 10 mL of volumetric flask 
and	volume	was	made	up	to	the	mark	with	diluent	to	get	5–50	10	μg/
mL concentrations of SER and DC (Table 1).
Fig. 8: Flow rate change - robustness: (3) Flow rate - 1.1 mL
Fig. 9: Composition change: 9% acetonitrile+42% MeOH+49% 
buffer
Fig. 10: Composition change - 10% acetonitrile +40% MeOH+ 
50% buffer
Fig. 11: Composition change - 11% acetonitrile +38% MeOH+ 
51% buffer
Fig. 12: Wavelength change: At 269 nm
Fig. 13: Wavelength change: At 270 nm
Fig. 14: Wavelength change: At 271 nm. The method was found to 
be robust as there was no  significant change in retention times
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Selection of mobile phase
Mixed solution of SER and DC was prepared and injected into the HPLC 
system. The solution was analyzed using buffer:methanol:ACN.
Selection of flow rate
Chromatogram of a mixed solution of SER (10 µg/mL) and DC 
(50 µg/mL) was studied at different flow rate such as 0.9, 1, and 
1.1 mL/min.
Selection of analytical wavelength
The standard solutions of SER (10 µg/mL) and DC (50 µg/mL) in 
mobile phase were scanned separately in the UV region of 200–400 nm, 
and the overlain spectra were recorded.
Chromatographic separation
Standard or sample solution of 20 µL was injected into the column. The 
chromatogram was run for 15 min with mobile phase, phosphate buffer 
pH 7 with OPA:methanol:ACN (5:4:1 v/v/v), which was previously 
sonicated for 10 min and detection done at wavelength 270 nm. 
The chromatogram was stopped after the separation was achieved 
completely. Data related to peak suc as area, height, retention time, and 
resolution were recorded using software.
Calibration curve for SER and DC
Aliquots of mix working standard solution of SER (5–50 µg/mL) 
and DC (5–50 µg/mL) were injected into the system with stated 
chromatographic conditions as described under table. The graph 
of the area of peak obtained versus respective concentration was 
plotted. The mean area and its standard deviation (SD) were 
calculated.
Validation of proposed method [5-15]
Precision
Repeatability
For repeatability, the separate concentration of 10 µg/mL for SER and 
50 µg/mL for DC was analyzed 5 times on the same day and % relative 
SD (% RSD) were calculated.
Intraday precision
Separate concentration of 10 µg/mL for SER and 50 µg/mL for DC was 
analyzed 5 times on the same day and % RSD was calculated.
Interday precision
Separate concentration of 10 µg/mL for SER and 50 µg/mL for DC was 
analyzed 5 times on the different days and % RSD was calculated.
Table 1: Preparation of mix working standard solution of SER 
and DC
Concentration (µg/mL) Volume (mL)
SER DC SER DC
5 5 0.05 0.05
10 10 0.1 0.1
15 15 0.15 0.15
20 20 0.2 0.2
25 25 0.25 0.25
30 30 0.3 0.3
35 35 0.35 0.35
40 40 0.4 0.4
45 45 0.45 0.45
50 50 0.5 0.5





* % drug found
SER DC SER DC SER DC
10 50 9.22 48.34 92.2 96.68
*Average of five determination. Buffer (pH-7) with OPA: methanol: ACN (5:4:1 
v/v/v) with Flow rate: 1.0 ml/min was selected, ACN: Acetonitrile
Table 3: Standard calibration data for DC
DC sodium












Table 4: Standard calibration data for SER
SER












Table 5: Statistical data for SER and DC by chromatographic 
method
Parameters SER DC
Linearity range (µg/mL) 5–50 5–50
Correlation coefficient 0.998 0.999
Slope 103.1 20.77
Intercept 98.05 5.409
LOD (µg/mL) 0.215 0.542
Linearity range for both SER and DC was found to be 5–50 µg/mL, 
SER: Serratiopeptidase, DC: Diclofenac, LOD: Limit of detection, LOQ: Limit of 
quantitation
Table 6: Repeatability data (statistical evaluation) bulk mix
Drugs *% Mean *SD *% RSD
SER 92.32 0.0454 0.0491
DC 94.12 0.6401 0.6800
*Average of five determinations, SER: Serratiopeptidase, DC: Diclofenac
Table 7: Repeatability data (statistical evaluation) tablet mix
Drugs *% Mean *SD *% RSD
SER 92.9 0.096 0.103
DC 94.04 0.640 0.680
*Average of five determinations. The % RSD is <2 for SER and DC which indicate 
that the method is precise, SER: Serratiopeptidase, DC: Diclofenac
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Accuracy
Procedure
Preparation of sample solution for SER
Recovery studies were carried out by pipetting out 0.1 mL from tablet 
stock solution in 10 mL volumetric flask and in that 0.8 mL (80%), 
1.0 mL (100%), and 1.1 mL (120%) bulk mixtures of DC and SER were 
added, and area was measured at the selected maximum wavelength.
The accuracy of the method was performed by conducting the standard 
edition method (80%, 100%, and 120% level) of tablet. The percentage 
recoveries were calculated and reported with SD and % RSD.
Specificity
The specificity of the HPLC method was ascertained by analyzing 
standard drug and sample solutions. The retention times of SER and DC 
in the sample solution were confirmed by comparing with that of the 
respective standards. The chromatogram of tablet sample showed only 
two peaks at retention time of 3.3833 and 8.1667 min for SER and DC, 
respectively, indicating that there is no interference of the excipients in 
the tablet formulation.
Limit of detection (LOD) and limit of quantitation (LOQ)
The LOD and LOQ were estimated from the set of three calibration 








Combined standard solution of SER (10 µg/mL) and DC (50 µg/mL) 
was prepared and analyzed 3 times. Chromatograms were studied for 
different parameters such as tailing factor, resolution, and theoretical 
plates to see that whether they comply with the recommended limit or 
out of recommended limit.
Analysis of tablet dosage form
An accurately weighed powder sample equivalent to 50 mg of DC 
and 10 mg of SER was transferred to 10 mL volumetric flask; 10 mL 
of phosphate buffer pH-7.0 was added, and the flask was sonicated 
for 5 min. Solution was filtered through 0.45 µ membrane filter paper. 
From the prepared solution, 0.1 mL of the filtrate was transferred to 
100 mL volumetric flask, and volume was made with mobile phase to 
get final concentration 50 µg/mL for DC and 10 µg/mL for SER. After 
setting the chromatographic conditions and stabilizing the instrument 
to obtain a steady baseline, the tablet sample solution was injected 
using 20 µL syringe filter. Chromatographic detection was carried out 
at 270 nm. Chromatogram was obtained, and peak areas were recorded. 
The procedure was repeated 5 times for the analysis of homogeneous 
sample.
RESULTS AND DISCUSSION
Selection of mobile phase
 Buffer	 (pH-7)	with	OPA:methanol:ACN	 (5:4:1	 v/v/v)	was	 selected	 as	
mobile phase with flow rate 1.0 ml/min. The chromatogram is shown 
in Fig. 3.  The proposed method was applied on 5 mixtures of SER and 
DC. The concentrations obtained are shown in Table 2.
Validation of proposed method
Linearity
The	linearity	range	for	SER	and	DC	was	found	to	be	5–50	μg/mL.
The linearity graphs and correlation coefficients are shown in Figs. 4 
and 5 for DC and SER . The data for calibration is given in Tables 3 and 4. 
The statistical data for linearity studies is given in Table 5.
Precision
The statistical data for repeatability studies for bulk mixture and tablet 
mixture are given in Tables 6 and 7.
Intra- and inter-day precision
Intraday precision was determined by analyzing SER and DC for 3 times 
in the same day. Interday precision was determined by analyzing SER 
and DC daily for different days. The results for inter-day and intra-day 
precision studies are shown in Table 8.
Accuracy
Recovery studies were carried out by applying the method of standard 
drug addiction at 80%, 100%, and 120% levels. The solutions for 
recovery studies at 80%, 100%, and 120% level were prepared. The 
solutions were filtered through a 0.45-µm membrane filter paper 
and analyzed by RP-HPLC method. At each level of recovery, three 
determinations were performed. The results of the same are shown in 
Table 9. The proposed method was found to be accurate.
Robustness
Robustness of the proposed method was studied by changing flow 
rate of mobile phase (0.9 ml/min, 1.0 ml/min and 1.1 ml/min), 
changing the composition of the mobile phase (9% acetonitrile+42% 
MeOH+49% buffer, 10% acetonitrile 40% MeOH+50% buffer and 11% 
acetonitrile+38% MeOH+51% buffer) and by changing the detection 
wavelength (269 nm, 270 nm and 271 nm). The chromatograms with 
changed flow rates are shown in Figs. 6-8. The chromatograms with 
changed mobile phase compositions are shown in Figs. 9-11. The 
chromatograms with changed detection wavelengths are shown in Figs. 
12-14. The statistical data for retention times and tailing factors for 
Table 8: Inter- and intra-day precision
Drugs Inter-day Intraday
%Mean SD %RSD %Mean SD %RSD
SER (BULK) 92.42 0.0516 0.0558 93.04 0.0472 0.0507
SER (TABLET) 92.38 0.0511 0.0553 92.82 0.0481 0.0518
DC (BULK) 94.12 0.6401 0.6800 94.12 0.6422 0.6823
DC (TABLET) 93.86 0.6386 0.6803 93.87 0.6386 0.6803
*Average of five determinations. The % RSD is <2 for SER & DC which indicate that the method is precise, SER: Serratiopeptidase, DC: Diclofenac
Table 9: Statistical validation of recovery studies





SER DC SER DC SER DC
80 92.74 98.92 0.0589 0.0152 0.063 0.0153
100 98.1 99.51 0.635 0.0115 0.647 0.0115
120 98.12 98.56 0.230 0.0057 0.234 0.0057
*Average of three at each level of recovery. The % recovery is within limit (98.0–
102.0%), so the method is accurate, SER: Serratiopeptidase, DC: Diclofenac
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Table 10: Flow rate change
Flow rate Retention time Tailing factor Area %Content
SER DC SER DC SER DC SER DC
0.9 3.4333 8.2167 0.7333 1.2333 1150.2328 2389.3639 101.5 101.88
1.0 3.3167 8.4500 1.3889 1.4286 831.2185 1988.1166 93.20 96.31
1.1 3.4167 8.2833 0.7667 1.2000 1035.22 2133.2555 101.36 99.89
SER: Serratiopeptidase, DC: Diclofenac
Table 11: Composition change
Composition change Retention time Tailing factor Area %Content
SER DC SER DC SER DC SER DC
42% MeOH+9% ACN+49% BUFFER 3.3500 8.3667 1.1000 1.4615 756.57 1646.64 73.34 77.57
CAN (10%)+MeOH (40%)+BUFFER (50%) PH 7.0 3.3167 8.4500 1.3889 1.4286 831.2185 1988.1166 92.5 96.62
38% MeOH+11% ACN+51% BUFFER 3.3500 8.6000 1.1667 1.3929 786.3861 1643.9059 76.23 79.97
SER: Serratiopeptidase, DC: Diclofenac, ACN: Acetonitrile
Table 12: Wavelength change
Wavelength change Retention time Tailing factor Area %Content
SER DC SER DC SER DC SER DC
269 3.3500 8.6000 1.1663 1.3919 776.3875 1643.8069 75.26 76.97
270 3.3167 8.4500 1.3889 1.4286 831.2185 1988.1166 93.5 96.62
271 3.3500 8.1333 1.0000 1.0625 1276.552 2303.7380 109.76 107.87
SER: Serratiopeptidase, DC: Diclofenac
Table 13: Details of chromatogram of DC and SER in tablet mix




SER 3.3833 1031.4727 0.9444 3570.5
DC 8.1667 2135.55 1.0625 3328.5
SER: Serratiopeptidase, DC: Diclofenac





% of label claim
SER DC SER DC SER DC
10 50 9.31 46.42 93.1 92.84
10 50 9.23 47.50 92.3 95
10 50 9.24 46.64 92.4 93.28
10 50 9.22 47.55 92.2 95.1
10 50 9.31 47.87 93.1 95.74
SER: Serratiopeptidase, DC: Diclofenac
Table 15: Validation parameters
Parameters SER DC
Linearity range (µg/mL) 5–50 5–50
Correlation coefficient 0.998 0.999
LOD (µg/mL) 0.215 0.542
LOQ (µg/mL) 0.653 1.643
Precision: bulk Intraday (% RSD) 0.0507 0.6823
Interday (% RSD) 0.0558 0.6800
Precision: Tablet intraday (% RSD) 0.0518 0.6803
Interday (% RSD) 0.0553 0.6803
Tailing factor 1.3889 1.4286
Mean % recovery bulk 92.32 94.12
Mean % recovery tablet 92.9 94.04
Theoretical plates 1814.8 2945.0
SER: Serratiopeptidase, DC: Diclofenac, LOD: Limit of detection, LOQ: Limit of 
quantitation
the flow rate change, mobile phase composition change and detection 
wavelength change are shown in Tables 10-12. The retention time is not 
affected significantly.   Thus, the proposed method was found to be robust.
Specificity
By comparing the chromatogram of diluent, standard solution, and test 
preparation solution, it was observed that there was no any interference 
of excipients with the peak of SER and DC, as shown in Figs. 15-17.
Fig. 15: Chromatogram of diclofenac
Fig. 16: Chromatogram of serratiopeptidase
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System suitability data
The system suitability data is shown in Table 13.
Application of the developed method to tablet formulation
The proposed validated method was successfully applied to the 
determination of SER and DC in its tablet dosage form (Fig. 18).
Summary of validation parameters
Summary of the validation parameters studied is given in Table 15. The 
proposed method was validated as per ICH Q2R1 guidelines.
 DISCUSSION
The literature survey gives few reported RP-HPLC methods for 
simultaneous estimation of DC sodium and SER in bulk and tablet 
dosage form. This work has made an attempt to develop a new RP-HPLC 
method for the estimation of DC sodium and SER in bulk and tablet 
dosage form. This work reports in detail, a more rigorously studied 
RP-HPLC method.
CONCLUSION
The proposed work concludes that the developed RP-HPLC method is 
simple, accurate, rapid, sensitive, precise, and economic. Hence, this 
method can be employed successfully for the estimation of SER and DC 
Fig. 17: Chromatogram of tablet mixture serratiopeptidase 
(10 µg/mL) and diclofenac (50 µg/mL)
Fig. 18: Chromatogram of tablet mixture
sodium in both bulk and tablet dosage forms.
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